Targeted therapy has officially entered the first-line standard of care for a high-risk molecular subset of metastatic colorectal cancer (mCRC). Pfizer Inc. announced that the U.S. FDA granted full approval to BRAFTOVI (encorafenib) in combination with ERBITUX (cetuximab) and fluorouracil-based chemotherapy for adults with BRAF…
Gastroenterology reimbursement continues to erode under Medicare and commercial payment models, even as operating costs, staffing pressures and inflation rise.…
The U.S. Food and Drug Administration has issued a medical device early alert for certain lots of AXIOS Stent and…
Colorectal cancer is on the rise among young people. Now it is the leading cause of cancer death in the…
FUJIFILM Healthcare Europe has announced that its latest 800-series duodenoscopes are now compatible with a newly CE-mark–approved sterilization cycle —…
As AI tools become embedded in clinical workflows—from note drafting to radiology…
Thought Leadership
Medical malpractice continues to be an occupational reality in gastroenterology. In fact,…
Pathologists Aren’t a Black Box: Why GI–Pathology Communication Directly Impacts Patient Car…
Smart toilets are moving from concept to clinical infrastructure. In a recent…